Loading...

Clinical Trials

Home / Clinical Trials

Clinical Trials

Apellis is currently conducting clinical trials around the world for an array of autoimmune and inflammatory diseases, with its lead candidate APL-2, a complement C3 inhibitor. We believe that our approach has the potential to effectively control many complement-dependent diseases.

Learn more about Apellis-sponsored ongoing clinical trials below.

Disease

Autoimmune Hemolytic Anemia (AIHA)

Study

PLAUDIT Clinical Trial: A phase 2, prospective, open-label study to assess the safety, tolerability, preliminary efficacy, pharmacokinetics and pharmacodynamics of multiple doses of APL-2 in patients with autoimmune hemolytic anemia (AIHA).

Status

Recruiting

Disease

Geographic Atrophy (GA)

Study

DERBY & OAKS Clinical Trials: Two Phase 3 Clinical Studies of APL-2 Therapy in Patients with GA

Status

Planned

Learn More

gastudy.com

Disease

Nephropathies

Study

DISCOVERY Clinical Trial: Phase 2 Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies

Status

Recruiting

Disease

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Study

PEGASUS Clinical Trial: A Phase III Study to Evaluate the Efficacy and Safety of APL-2 in Patients with Paroxysmal Nocturnal Hemoglobinuria

Status

Recruiting

Learn More

pnhstudy.com

Disease

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Study

PALOMINO Clinical Trial: A phase IIa, open-label study to evaluate the efficacy and safety of APL-2 in patients with PNH who have never been treated with eculizumab

Status

Planned

Learn More

clinicaltrials.gov.

Disease

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Study

PADDOCK Clinical Trial: Pilot Study to Assess Safety, Preliminary Efficacy and Pharmacokinetics of Subcutaneous APL-2 in PNH Subjects

Status

Recruiting

Learn More

clinicaltrials.gov

Disease

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Study

PHAROAH Clinical Trial: A Phase I Study to Assess the Safety of APL-2 as an Add-On to Standard of Care in Subjects with PNH

Status

Active, not recruiting

Learn More

clinicaltrials.gov

Disease

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Study

An Open Label, Non-Randomized, Multi-Center Extension Study for ongoing and planned Phase IB, Phase II, and Phase III studies with APL-2 in subjects with PNH

Status

Planned

Learn More

clinicaltrials.gov


Apellis logo
© Apellis Pharmaceuticals 2018.